Vectura News Discover more about our company, science, innovation and people with the latest headlines from Vectura.
Vectura Group appoints Jeanne Hecht and Jeanne Thoma to its Board of Directors Published30/12/2020 Read more
Vectura earns $11m milestone as Hikma receives US FDA approval for generic Advair Diskus® Published17/12/2020 Read more
Vectura Expands Capabilities to Handle and Develop Highly Potent Inhaled Drugs at its Facility in Chippenham, U.K. Published14/12/2020 Read more
Vectura signs agreement with Kinaset Therapeutics Inc. to support the development of VR588 to treat asthma Published30/11/2020 Read more
Will Downie’s podcast: “There’s a patient at the end of every piece of work we do…” Published08/10/2020 Read more
Vectura shortlisted for ’Excellence in Pharma: Contract Services and Outsourcing’ Published24/09/2020 Read more
Vectura partners with Monash University to support development of inhaled oxytocin to prevent postpartum haemorrhage Published14/09/2020 Read more
Live Webcast 24th June: Dry Powder Inhalers – Key Considerations for Combination Product Development Published17/06/2020 Read more
Vectura expands business development team with three global appointments Published03/06/2020 Read more
Sharon Johnson appointed Executive Vice President for Delivery Management Published10/02/2020 Read more
Pre-close trading update confirms 2019 trading in-line with expectations Published13/01/2020 Read more
Vectura to present latest science at Drug Delivery to the Lungs (DDL) 2019 Published22/10/2019 Read more
Vectura wins US GSK patent litigation and awarded $89.7m in damages by jury Published26/04/2019 Read more
Global agreement with Hikma to develop generic versions of GSK’s Ellipta® portfolio Published08/11/2018 Read more
